Clinical evidence and trial services
Clinical-trial design, patient and site management, monitoring, data management and evidence-generation services supporting regulatory submissions and payer coverage.
Intelligence / Healthtech & medtech market map / Clinical and regulatory support services
Services that help medtech, diagnostics, digital-health and life-science vendors obtain market access and demonstrate safety, effectiveness and quality. Includes regulatory consulting and submissions, clinical trials and evidence generation, quality and compliance support, health-economic and reimbursement advice, and market-access services. Excludes physical products, software licences and device installation or maintenance.
Split by product or service.
Clinical-trial design, patient and site management, monitoring, data management and evidence-generation services supporting regulatory submissions and payer coverage.
Advice, documentation, testing and submission support for regulatory approval and market authorisation across jurisdictions, including quality-system and technical-file preparation
Quality-system implementation, compliance audits, post-market surveillance, vigilance, risk-management and product-lifecycle regulatory support.
Health-economic assessments, reimbursement dossiers, pricing analysis, payer-engagement strategy and commercial launch support for technologies.
$8.5B ($5.5B–$11.2B) · 2025 · Triangulated
Sector defined as clinical and regulatory support services for medtech, diagnostics, digital-health and life-science vendors. Published healthcare regulatory affairs outsourcing estimates cluster at USD 7.5B (2024) rising to USD 8.1B (2025) [9], USD 8.20B (2025) [6], USD 8.40B (2025) [5], USD 8.95B (2025) and USD 9.67B (2026) [10], USD 9.37B (2026) [3], USD 11.20B (2025) [7], and USD 5.5B (2025) [8]. These are pharma-plus-device and include legal representation and writing/publishing, so they overstate the medtech/diagnostics-focused scope; the medtech-specific device regulatory affairs outsourcing line is USD 2.1B (2024) [2]. Sector midpoint taken at USD 8.5B for 2025 with a USD 5.5-11.2B range; forecast anchored on USD 17.9B by 2034 [10] and USD 18.6B by 2034 [5].
// Sell into Clinical and regulatory support services